Inhibition of Lung Adenocarcinoma Growth by using Oridonin
DOI:
https://doi.org/10.61173/0f01c260Keywords:
oridonin, lung adenocarcinoma, notch pathwayAbstract
The abnormal activity of the Notch signal pathway is a common manifestation of many cancerous cells. Therefore,
blocking the notch pathway of cancer cells positively affects cancer treatment. Because oridonin directly acts on the
target notch receptor 1-4 cancer cells, inhibiting the Notch signaling pathway can inhibit the growth of cancer cells.
References
[1] Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022). Notch signaling pathway: architecture, disease, Dean&Francis and therapeutics. Signal transduction and targeted therapy, 7(1), 95. https://doi.org/10.1038/s41392-022-00934-y
[2] He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., Liu, Q., Liang, G., Deng, X., Jiang, W., & Zhou, R. (2018). Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature communications, 9(1), 2550. https://doi. org/10.1038/s41467-018-04947-6
[3] Xia, S., Zhang, X., Li, C., & Guan, H. (2017). Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 25(4), 638–643. https://doi.org/10.1016/j.jsps.2017.04.037
[4] Miller, L. H., & Su, X. (2011). Artemisinin: discovery from the Chinese herbal garden. Cell, 146(6), 855–858. https://doi. org/10.1016/j.cell.2011.08.024
[5] Wang, M., Xu, B., Liu, L., & Wang, D. (2022). Oridonin attenuates dextran sulfate sodiuminduced ulcerative colitis in mice via the Sirt1/NFκB/p53 pathway. Molecular medicine reports, 26(4), 312. https://doi.org/10.3892/mmr.2022.12828
[6] Mokhtari T. (2022). Targeting autophagy and neuroinflammation pathways with plant-derived natural compounds as potential antidepressant agents. Phytotherapy research : PTR, 36(9), 3470–3489. https://doi.org/10.1002/ ptr.7551
[7] Li, X., Zhang, C. T., Ma, W., Xie, X., & Huang, Q. (2021). Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Frontiers in pharmacology, 12, 645824. https://doi. org/10.3389/fphar.2021.645824
[8] Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016). Cancer statistics in China, 2015. CA: a cancer journal for clinicians, 66(2), 115–132. https://doi.org/10.3322/caac.21338
[9] Hutchinson, B. D., Shroff, G. S., Truong, M. T., & Ko, J. P. (2019). Spectrum of Lung Adenocarcinoma. Seminars in ultrasound, CT, and MR, 40(3), 255–264. https://doi. org/10.1053/j.sult.2018.11.009
[10] Li, L., Krantz, I. D., Deng, Y., Genin, A., Banta, A. B., Collins, C. C., Qi, M., Trask, B. J., Kuo, W. L., Cochran, J., Costa, T., Pierpont, M. E., Rand, E. B., Piccoli, D. A., Hood, L., & Spinner, N. B. (1997). Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nature genetics, 16(3), 243–251. https://doi. org/10.1038/ng0797-243
[11] Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022). Notch signaling pathway: architecture, disease, and therapeutics. Signal transduction and targeted therapy, 7(1), 95. https://doi.org/10.1038/s41392-022-00934-y
[12] Myers, D. J., & Wallen, J. M. (2022). Lung Adenocarcinoma. In StatPearls. StatPearls Publishing.
[13] Kumar, P., Nagarajan, A., & Uchil, P. D. (2018). Analysis of Cell Viability by the MTT Assay. Cold Spring Harbor protocols, 2018(6), 10.1101/pdb.prot095505. https://doi. org/10.1101/pdb.prot095505
[14] Zhang, M., Han, Y., Zheng, Y., Zhang, Y., Zhao, X., Gao, Z., & Liu, X. (2020). ZEB1-activated LINC01123 accelerates the malignancy in lung adenocarcinoma through NOTCH signaling pathway. Cell death & disease, 11(11), 981. https://doi. org/10.1038/s41419-020-03166-6
[15] Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. North American journal of medical sciences, 4(9), 429–434. https://doi. org/10.4103/1947-2714.100998
[16] Gui, Z., Luo, F., Yang, Y., Shen, C., Li, S., & Xu, J. (2017). Oridonin inhibition and miR200b3p/ZEB1 axis in human pancreatic cancer. International journal of oncology, 50(1), 111– 120. https://doi.org/10.3892/ijo.2016.3772
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
